Johnson & Johnson is not one to avoid pharmacogenomics for fear that it will hasten the downfall of the blockbuster model. Rather, the drug maker has been collecting DNA samples routinely in clinical trials for several years and using a variety of genomic strategies to enhance the safety and efficacy of its drug candidates.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.